Ozempic, tirzepatide and other GLP-1RAs - impact on ME/CFS


A US remote trial investigating the impact of tirzepatide on Long Covid
 
Very soon I’ll be evaluating the difference between Mounjaro and Wegovy / tirzepatide and ozempic
Me too.
I haven't seen any studies looking at those who have transitioned and whether they can maintain good results on Wegovy after being on Mounjaro.

My GP has told me that around Xmas there should be more weight loss drugs being released. I know Eli Lilly have another drug in preparation but, when I last read about it, the Phase 3 trials hadn't been completed so I don't think that will reach the market for a while. I may be wrong.


edit: sorry I've mistaken the thread. I have had no increase in energy while on mounjaro: currently 11 months.
 
Me too.
I haven't seen any studies looking at those who have transitioned and whether they can maintain good results on Wegovy after being on Mounjaro.

My GP has told me that around Xmas there should be more weight loss drugs being released. I know Eli Lilly have another drug in preparation but, when I last read about it, the Phase 3 trials hadn't been completed so I don't think that will reach the market for a while. I may be wrong.


edit: sorry I've mistaken the thread. I have had no increase in energy while on mounjaro: currently 11 months.
I assume that there should be “some” continuing effect because both contain a GLP-1 receptor agonist.
Wegovy was always the slower losses/less losses overall when compared in trials though.
 
This may be what my GP was referring to. From the Independent-

"Eli Lilly and Company announced promising results for its next-generation weight-loss drug Thursday, with patients losing up to 20.1 percent of their body weight on eloralintide.

The once-weekly amylin analog injection could be an enticing alternative for people looking to reap the benefits of the most popular weight-loss drugs on the market without one of their least-favorable side effects.

Previous studies have shown that amylin analog drugs - which imitate the body’s natural production of the blood sugar-regulating hormone amylin - may lead to a lower loss of lean muscle mass than do GLP-1 drugs like Ozempic and Wegovy, among others.

The 11-month Phase 2 trial, which included 263 participants who are overweight or living with obesity, also showed improvements in blood pressure, blood sugar and in markers of inflammation.

"Obesity is a complex condition, and no single treatment works for everyone,” Dr. Liana Billings, Director of Clinical and Genetics Research in Diabetes and Cardiometabolic Disease at Endeavor Health, said in a statement."
 
Should people with ME be concerned about loss of muscle mass while taking these drugs? I noticed that as long as you didn’t have an underweight BMI, you could still qualify for the LoCITT trial. But presumably then a lot of people could qualify even if they don’t want to lose any weight or muscle…
 
Back
Top Bottom